metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Efectos de la oxitetraciclina sobre el hígado de rata
Journal Information
Vol. 25. Issue 9.
Pages 529-533 (January 2002)
Share
Share
Download PDF
More article options
Vol. 25. Issue 9.
Pages 529-533 (January 2002)
Full text access
Efectos de la oxitetraciclina sobre el hígado de rata
Effects of oxytetracycline on rat liver
Visits
5714
L. Pastor, L. del Olmo
Corresponding author
delolmo@uva.es

Correspondencia: Dra. L. del Olmo Martínez. Federico Landrove, 14, 3.°. 47014 Valladolid
, C. Lorenzo, A. Almaraz, A. Belmonte, M.C. Coca, A. Caro-Patón
Departamento de Medicina. Facultad de Medicina. Universidad de Valladolid. España
This item has received
Article information
Objetivos

Este proyecto experimental ha sido diseñado para evaluar: a) la capacidad de la oxitetraciclina para inducir esteatosis en el hígado de rata cuando es administrada durante un período prolongado; b) evaluar si las ratas hembras son más susceptibles a este fármaco, y c) estudiar las posibles alteraciones ultraestructurales y su relación con los mecanismos de la esteatosis.

MéTodos

Sesenta y dos ratas Wistar (31 machos y 31 hembras) fueron distribuidas en 6 grupos, dos grupos control y cuatro grupos experimentales. El estudio duró 3 meses. Se obtuvo sangre y tejido hepático bajo anestesia para el estudio morfológico (microscopia óptica [MO] y microscopia electrónica [ME]).

Resultados

La esteatosis fue de tipo microvesicular con una distribución periportal. Apareció en los grupos tratados, con un grado significativamente mayor en las hembras (p = 0,004). No se observó ninguna relación con la dosis. El estudio ultraestructural reveló una dilatación de los microsomas en todos los grupos experimentales, sin diferencias en cuanto al sexo. No se constató una proliferación de los peroxisomas ni la aparición alteraciones mitocondriales.

Conclusiones

La oxitetraciclina produce predominantemente esteatosis hepática microvesicular, apareciendo fundamentalmente en hembras. Como posible mecanismo de esta esteatosis inducida por oxitetraciclina postulamos un descenso en las funciones mitocondrial, microsomal y peroxisomal como resultado de una inhibición en la síntesis proteica de estos compartimientos celulares.

Objectives

This experimental project was designed to evaluate: a) the capacity of oxytetracycline to induce microvesicle steatosis in rat liver when administered over long time periods; b) whether female rats are more susceptible to this substance, and c) the possible ultrastructural alterations and their relation to the mechanisms of steatosis.

Methods

Sixty-two Wistar rats (31 males and 31 females) were distributed into six groups, two control groups and four experimental groups. The experiment lasted three months. Blood and hepatic tissue samples were extracted under anesthesia for morphologic study (optical and electron microscopy).

Results

Steatosis was of the microvesicular type with mainly periportal distribution. Steatosis developed in the treated groups and the degree was significantly greater in the females (p = 0.004). No relationship was found with dose. Ultrastructural study revealed microsome dilation in all experimental groups, with no differences according to sex. Despite the steatosis, no proliferation of peroxisomes or mitochondrial alterations were observed.

Conclusions

Oxytetracycline produced predominantly periportal microvesicular hepatic steatosis, appearing mostly in the females. As a possible mechanism for tetracycline-induced steatosis, we postulate a decrease in mitochondrial, peroxisome and microsome function as a result of protein synthesis inhibition in these cell compartments.

Full text is only aviable in PDF
Bibliografía
[1.]
H.J. Zimmerman.
Agents employed in the treatment of infectious and parasitic diseases.
Hepatotoxicity, pp. 468-509
[2.]
H.J. Zimmerman.
Hepatotoxicity.
Dis Month, 39 (1993), pp. 675-787
[3.]
D. Larrey.
Hepatites medicamenteuses: aspects epidemiologiques, cliniques, diagnostiques et physiopathologiques in 1995.
Rev Med Intern, 16 (1995), pp. 752-758
[4.]
B.H. Stricker, P. Spoelstra.
Antimicrobial agents.
Drug-induced hepatic injury, pp. 137-193
[5.]
M.H. Lepper, H.J. Zimmerman, G. Carroll.
Effect of large doses of aureomycin, terramycin, and chloramphenicol on livers of mice and dogs.
Arch Intern Med, 88 (1951), pp. 284-295
[6.]
P.J. Whalley, R.H. Adams, B. Combes.
Tetracycline toxicity in pregnancy. Liver and pancreatic dysfunction.
JAMA, 189 (1964), pp. 357-362
[7.]
C.T. Kunelis, J.L. Peters, H.A. Edmondson.
Fatty liver of pregnancy and its relationship to tetracycline therapy.
Am J Med, 38 (1965), pp. 359-377
[8.]
J.D. Lloyd-Still, R.J. Grand, G.F. Vawter.
Tetracycline hepatotoxicity in the differential diagnosis of postoperative jaundice.
J Pediatr, 84 (1974), pp. 366-370
[9.]
E.S. Allen, W.E. Brown.
Hepatic toxicity of tetracycline in pregnancy.
Am J Obstet Gynecol, 95 (1966), pp. 12-18
[10.]
B. Fromenty, D. Pessayre.
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.
Pharmac Ther, 67 (1995), pp. 101-154
[11.]
K.J. Breen, S. Schenker, M. Heimberg.
Fatty liver induced by tetracycline in the rat. Dose-response relationships and effect of sex.
Gastroenterology, 69 (1975), pp. 714-723
[12.]
E. Freneaux, G. Labbe, P. Letteron.
Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic.
Hepatology, 8 (1988), pp. 1056-1062
[13.]
G. Labbe, B. Fromenty, E. Freneaux.
Effects of various tetracycline derivatives on in vitro and in vivo β-oxidation of fatty acids, egress of triglycerides from the liver, accumulation of hepatic triglycerides, an mortality in mice.
Biochem Pharmacol, 41 (1991), pp. 638-641
[14.]
C. Bogert, A.M. Kroon.
Tissue distribution and effects on mitochondrial protein synthesis of tetracyclines after prolonged continuous intravenous administration to rats.
Biochem Pharmacol, 30 (1981), pp. 1706-1709
[15.]
C. Bogert, M. Holtrop, T.E. Melis, P.R. Roefsema, A.M. Kroon.
Different effects of oxytetracycline and doxycycline on mitochondrial protein synthesis in rat liver after long-term treatment.
Biochem Pharmacol, 36 (1987), pp. 1555-1559
[16.]
D. Deboyser, F. Goethals, G. Krack, M. Roberfroid.
Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes.
Toxicol Appl Pharmacol, 97 (1989), pp. 473-479
[17.]
H.G. Du Buy, J.L. Showacre.
Selective localization of tetracycline in mitochondria of living cells.
Science, 133 (1961), pp. 196-197
[18.]
M.H. Lepper, C.K. Wolfe, H.J. Zimmerman, E.R. Caldwell Jr, H.W. Spies, H.F. Dowling.
Effect of large doses of aureomycin on human liver.
Arch Intern Med, 88 (1951), pp. 271-283
[19.]
L.D. Wruble, A.J. Ladman, L.G. Britt, A.J. Cummins.
Hepatotoxicity produced by tetracycline overdosage.
JAMA, 192 (1965), pp. 92-94
[20.]
R.W. Van Dyke.
The liver in pregnancy.
Hepatology: a textbook of liver disease, pp. 1734-1750
[21.]
J.R. Barton, C.A. Riely, T.A. Adamec, D.R. Shanklin, A.D. Khoury, B.M. Sibai.
Hepatic histopathologic condition does not correlate with laboratory abnormalities in HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count).
Am J Obstet Gynecol, 167 (1992), pp. 1538-1543
[22.]
C.A. Riely.
Hepatic disease in pregnancy.
Am J Med, 96 (1994), pp. S18-S22
[23.]
M. Miguil, A. Sadraoui, S. Moutaouakkil, B. Idali, M. Ghazli, M. Benaguida.
La stéatose hépatique aigüe gravidique peut guérir malgré la poursuite de la grossesse.
J Gynecol Obstet Biol Reprod, 23 (1994), pp. 308-310
[24.]
I.M. Usta, J.B. Barton, E.A. Amon, A. González, B.M. Sibai.
Acute fatty liver of pregnancy: an experience in the diagnosis and management of fourteen cases.
Am J Obstet Gynecol, 171 (1994), pp. 1342-1347
[25.]
H. Reyes, L. Sandoval, A. Wainstein.
Acute fatty liver of pregnancy: a clinical study of 12 episodes in 11 patients.
Gut, 35 (1994), pp. 101-106
[26.]
V.M. Sborov, D.A. Sutherland.
Fatty liver following aureomycin and terramycin therapy in chronic hepatic disease.
Gastroenterology, 18 (1951), pp. 598-605
[27.]
M.A. Sande, G.L. Mandell.
Agentes antimicrobianos: tetraciclinas, cloranfenicol, eritromicina y agentes antibacterianos varios.
Las bases farmacológicas de la terapéutica, pp. 1083-1120
[28.]
D.E. Amacher, B.A. Martin.
Tetracycline-induced steatosis in primary canine hepatocyte cultures.
Fundam Appl Toxicol, 40 (1997), pp. 256-263
[29.]
M. Jiménez-Rodriguezvila, A. Caro-Patón, A. Dueñas-Laita.
Histological, ultrastructural and mitochondrial oxidative phosphorylation studies in liver of rats chronically treated with oral valproic acid.
J Hepatol, 1 (1985), pp. 453-465
[30.]
M.A. MacLean, A.D. Cameron, G.P. Cumming, K. Murphy, P. Mills, K.J. Hilan.
Recurrence of acute fatty liver of pregnancy.
Br J Obstet Gynaecol, 101 (1994), pp. 453-454
[31.]
J. Peters, G.J. Wiener, J. Gilliam, G. Noord, K.R. Geisinger, E.S. Roach.
Reye's syndrome in adults.
Arch Intern Med, 146 (1986), pp. 2401-2403
[32.]
W.B. Poss, D.D. Vernon, J.M. Dean.
A reemergence of Reye's syndrome.
Arch Pediatr Adolesc Med, 148 (1994), pp. 879-882
[33.]
M.A. Peters, J.R. Fouts.
The inhibitory effect of aureomycin (chlortetracycline) pretreatment on some rat liver microsomal enzyme activities.
Biochem Pharmacol, 18 (1969), pp. 1511-1517
[34.]
S. Sherlock.
Clinical techniques for the evolution of therapeutic agents on the liver.
Liver and drugs, pp. 193-205
[35.]
M.J. Philhps, P.S. Latham, S. Poucel.
Electron microscopy of human liver diseases.
Diseases of the liver, pp. 47-62
[36.]
G.H. Millward-Sadler, A.M. Jezequel.
Normal histology and ultraestructure.
Liver and biliary disease, pp. 13-23
[37.]
A. Berkaloff, J. Bourguet, P. Favard, J.C. Lacroix.
Retículo endoplásmico.
Biología y fisiología celular, pp. 229-243
[38.]
A.M. Jezequel, F. Orlandi.
Fine morphology of the human liver as a tool in clinical pharmacology.
Liver and drugs, pp. 145-165
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos